Tasigna (Nilotinib) - Chronic Myeloid Leukemia - CML
''Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor...
It was approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after five months of treatment... 'Extract of Wikipedia
Important Safety Information About TASIGNA
SITES
Tasigna by Novartis
Nilotinib Information by Nilotinib.org
Tasigna by Drugs.com
FORUMS
Tasigna Talk by newcmldrug.com
Tasigna on Facebook.
VIDEOS
Gary Gonzales - Tasigna patient video
Tasigna by Novartis
Nilotinib Information by Nilotinib.org
Tasigna by Drugs.com
FORUMS
Tasigna Talk by newcmldrug.com
Tasigna on Facebook.
VIDEOS
Gary Gonzales - Tasigna patient video
Nilotinib Associated With Increased Peripheral Artery Disease
Rate in CML
May 13, 2013, Cancer Network
TASIGNA (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the Public
April 12, 2013, Health Canada
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
July 5, 2012, PubLmed
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
May 24, 2012, Unbound Medline
May 13, 2013, Cancer Network
TASIGNA (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the Public
April 12, 2013, Health Canada
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
July 5, 2012, PubLmed
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
May 24, 2012, Unbound Medline
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete genetic response during first-line nilotinib therapy.
April 19, 2012, PubLMed
April 19, 2012, PubLMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire
FDA approves update for Tasigna label
December 15, 2011, Modern Medicine
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
November 11, 2011, PubMed
Nilotinib Beats Imatinib at 24 Months in Treatment of CML
June 20, 2011, Medscape Today
Nilotinib Superior to Imatinib, Fewer Mutations in Treatment of CML-CP
June 6, 2011, Monthly Prescribing Reference
Nilotinib for Myeloid Leukemia VIDEO
December 7, 2010, Oncology Stat
ASH 2010: Nilotinib promising for early chronic phase, Philidelphia-positive chronic myeloid leukaemia
December 4, 2010, Ecancermedicalscience
Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010, ASH 2010, Orlando
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Living with chronic myeloid leukemia (Tasigna is approved in Canada) VIDEO
August 2010, Info4YourLife
Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. F1000: Ranked "Exceptional" and "Changes Clinical Practice"
July 2010, Medscape Today
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
June 5, 2010, The New England Journal of Medecine
Tasigna versus Gleevec VIDEO
June 16, 2010, Insidermedecine
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
December 9, 2009, Insciences organisation
Nilotinib for the frontline treatment of Ph+ chronic leukemia
December 3, 2009, Blood, Vol.114, No.24, pp.493304938
EHA 2009: Nilotinib Superior in Chronic Myeloid Leukemia Than Current Standard
June 2009, Medscape
The Consumer Information Section (Part III) of the Product Monograph for TASIGNA
June 2009, Health Canada
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
When Imatinib and Dasatinib Fail, Nilotinib May Be an Option for CML
April 2008, Clinical Oncology
January 22, 2012, PubLMed
The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders
December 19, 2011, PRNewswire
FDA approves update for Tasigna label
December 15, 2011, Modern Medicine
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
November 11, 2011, PubMed
Nilotinib Beats Imatinib at 24 Months in Treatment of CML
June 20, 2011, Medscape Today
Nilotinib Superior to Imatinib, Fewer Mutations in Treatment of CML-CP
June 6, 2011, Monthly Prescribing Reference
Nilotinib for Myeloid Leukemia VIDEO
December 7, 2010, Oncology Stat
ASH 2010: Nilotinib promising for early chronic phase, Philidelphia-positive chronic myeloid leukaemia
December 4, 2010, Ecancermedicalscience
Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010, ASH 2010, Orlando
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN
Living with chronic myeloid leukemia (Tasigna is approved in Canada) VIDEO
August 2010, Info4YourLife
Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. F1000: Ranked "Exceptional" and "Changes Clinical Practice"
July 2010, Medscape Today
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
June 5, 2010, The New England Journal of Medecine
Tasigna versus Gleevec VIDEO
June 16, 2010, Insidermedecine
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
December 9, 2009, Insciences organisation
Nilotinib for the frontline treatment of Ph+ chronic leukemia
December 3, 2009, Blood, Vol.114, No.24, pp.493304938
EHA 2009: Nilotinib Superior in Chronic Myeloid Leukemia Than Current Standard
June 2009, Medscape
The Consumer Information Section (Part III) of the Product Monograph for TASIGNA
June 2009, Health Canada
Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday
When Imatinib and Dasatinib Fail, Nilotinib May Be an Option for CML
April 2008, Clinical Oncology
